Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $12.63, for a total transaction of $694,650.00. Following the completion of the transaction, the chief executive officer now directly owns 221,017 shares of the company's stock, valued at approximately $2,791,444.71. This trade represents a 19.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, May 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.71, for a total transaction of $699,050.00.
• On Monday, April 21st, Saurabh Saha sold 14,656 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.29, for a total transaction of $180,122.24.

Centessa Pharmaceuticals Trading Down 2.0%

Shares of NASDAQ:CNTA traded down $0.25 on Friday, hitting $12.43. 1,612,616 shares of the company's stock were exchanged, compared to its average volume of 718,940. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -6.87 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $8.46 and a 12 month high of $19.09. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37. The business's 50 day simple moving average is $12.70 and its two-hundred day simple moving average is $14.87.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. Analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on CNTA. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Chardan Capital initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price target for the company. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 price objective for the company. Morgan Stanley reissued an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price for the company. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.89.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CNTA. Geode Capital Management LLC boosted its holdings in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock valued at $959,000 after purchasing an additional 660 shares during the period. GF Fund Management CO. LTD. bought a new stake in Centessa Pharmaceuticals during the 4th quarter valued at $31,000. Trexquant Investment LP lifted its holdings in shares of Centessa Pharmaceuticals by 1.1% in the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company's stock worth $3,796,000 after buying an additional 2,810 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after buying an additional 3,194 shares during the period. Finally, Osterweis Capital Management Inc. bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $47,000. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.